According to the Business Market Insights The Global Diagnostic CDMO Market is witnessing substantial growth as healthcare companies increasingly outsource diagnostic product development and manufacturing to specialized contract organizations. Diagnostic Contract Development and Manufacturing Organizations (CDMOs) play a crucial role in supporting medical device companies, biotechnology firms, and pharmaceutical organizations with product design, assay development, regulatory support, packaging, and large-scale manufacturing solutions.

According to Business Market Insights, the global Diagnostic CDMO Market was valued at US$ 44.12 billion in 2025 and is projected to reach US$ 105.24 billion by 2033, expanding at a CAGR of 11.48% during the forecast period from 2026 to 2033. The market growth is strongly driven by increasing demand for point-of-care diagnostics, rapid technological advancements in molecular diagnostics, and rising prevalence of chronic and infectious diseases worldwide.

The growing focus on precision medicine and personalized healthcare has significantly accelerated the adoption of diagnostic outsourcing services. Diagnostic manufacturers are increasingly collaborating with CDMOs to reduce operational costs, accelerate product commercialization, and improve manufacturing scalability. In addition, the increasing complexity of diagnostic devices and stringent global regulatory standards are encouraging companies to seek specialized outsourcing expertise.

Download Sample PDF

https://www.businessmarketinsights.com/sample/BMIPUB00032349

Market Drivers

Rising Demand for Point-of-Care Diagnostics

One of the major growth drivers for the Diagnostic CDMO Market is the increasing adoption of point-of-care (POC) diagnostic solutions. Healthcare providers and patients are demanding rapid and accurate testing solutions that can deliver real-time clinical results outside centralized laboratories. This trend is driving demand for compact, portable, and user-friendly diagnostic devices.

CDMOs are becoming essential partners for OEMs seeking expertise in miniaturization technologies, assay integration, automation, and portable diagnostic system development. The rapid expansion of infectious disease testing and home healthcare monitoring solutions continues to strengthen market demand globally.

Growth in Molecular Diagnostics and Precision Medicine

The increasing popularity of molecular diagnostics and genomic testing is another key factor fueling market growth. Precision medicine requires highly specialized companion diagnostic solutions capable of delivering accurate patient-specific data. Diagnostic CDMOs offer advanced capabilities in assay design, biomarker validation, clinical testing, and scalable manufacturing, enabling pharmaceutical companies to accelerate product development timelines.

The rising adoption of oncology diagnostics, genetic testing, and personalized therapeutics is creating long-term growth opportunities for CDMO service providers worldwide.

Increasing Outsourcing by Diagnostic Manufacturers

Diagnostic companies are increasingly outsourcing manufacturing and development operations to reduce capital expenditure and improve operational efficiency. Outsourcing allows companies to access advanced production technologies without investing heavily in infrastructure. This trend is particularly strong among startups and mid-sized diagnostic firms seeking faster market entry and regulatory compliance support.

The growing complexity of regulatory requirements, especially in regions such as Europe and North America, has further increased reliance on experienced CDMO partners capable of navigating evolving compliance standards.

Market Segmentation

By Service

Based on service, the market is segmented into:

• Contract Manufacturing
• Contract Development
• Packaging
• Labelling & Sterilization
• Regulatory Affairs
• Others

Among these, the contract manufacturing segment dominates the market due to increasing outsourcing of large-scale production activities by diagnostic companies. The contract development segment is expected to witness the fastest growth during the forecast period owing to rising demand for end-to-end development services.

By Class

The market is categorized into:

• Class I
• Class II
• Class III

Class II devices currently account for a significant market share because of their widespread use in blood glucose monitoring systems, immunoassay analyzers, and molecular diagnostic kits.

By Application

Key application segments include:

• Infectious Disease Diagnostics
• Oncology Diagnostics
• Cardiometabolic Diagnostics
• Genetic & Genomic Testing
• Respiratory & Critical Care Diagnostics
• Others

The infectious disease diagnostics segment continues to lead the market due to growing global demand for rapid testing technologies and disease surveillance systems.

By End Use

The market is segmented into:

• Original Equipment Manufacturers (OEMs)
• Pharmaceutical & Biopharmaceutical Companies
• Others

Pharmaceutical and biopharmaceutical companies are emerging as high-growth end users due to increasing demand for companion diagnostics linked with targeted therapies.

Regional Insights

North America

North America holds a dominant share in the Diagnostic CDMO Market due to the strong presence of biotechnology firms, advanced healthcare infrastructure, and growing investments in molecular diagnostics. The United States remains a key innovation hub for diagnostic product development and outsourcing activities.

Europe

Europe represents a significant market owing to stringent regulatory frameworks such as the In Vitro Diagnostic Regulation (IVDR). Diagnostic manufacturers increasingly rely on CDMOs with strong regulatory expertise to ensure compliance and faster product approvals.

Asia Pacific

Asia Pacific is expected to witness the fastest market growth during the forecast period. Countries such as China, India, Japan, and South Korea are becoming major manufacturing hubs due to lower production costs, skilled workforce availability, and increasing healthcare investments. Global OEMs are increasingly shifting manufacturing operations to Asia Pacific to optimize supply chains and reduce operational risks.

Recent Developments

Several strategic developments are shaping the competitive landscape of the Diagnostic CDMO Market:

• In June 2025, Zydus Lifesciences announced its entry into the biologics CDMO market through the acquisition of manufacturing facilities from Agenus.
• In April 2025, Roche announced a US$ 50 billion investment in pharmaceutical and diagnostics manufacturing expansion in the United States.
• In February 2025, Jabil Inc. acquired Pharmaceutics International Inc. to strengthen its aseptic filling and pharmaceutical manufacturing capabilities.

Market Opportunities

The Diagnostic CDMO Market presents significant growth opportunities in:

• AI-driven digital diagnostics
• Companion diagnostics
• Home healthcare diagnostics
• Wearable diagnostic technologies
• Personalized medicine
• Advanced molecular testing

The integration of artificial intelligence and automation in diagnostic platforms is expected to create new business opportunities for CDMOs specializing in next-generation manufacturing technologies.

Competitive Landscape and Key Players

Leading companies operating in the Global Diagnostic CDMO Market include:

• Jabil Inc.
• Thermo Fisher Scientific Inc.
• Integer Holdings Corporation
• FLEX Ltd.
• Sanmina Corporation
• Celestica Inc.
• Phillips-Medisize
• Plexus Corp.
• Nipro Corporation
• Viant Technology LLC

These companies are actively investing in advanced manufacturing technologies, strategic acquisitions, and global expansion initiatives to strengthen their market presence.

Trending Keywords –

Diagnostic Catheter Market - Outlook (2022-2033)

Dental Diagnostic and Surgical Equipment Market - Outlook (2022-2033)

Digital Diagnostics Market - Outlook (2022-2033)

Future Outlook

The future outlook for the Global Diagnostic CDMO Market remains highly promising. Increasing adoption of decentralized diagnostics, expansion of personalized healthcare, and growing investments in molecular diagnostics are expected to drive long-term market growth. Diagnostic companies will continue to rely on CDMOs for innovation, regulatory expertise, and scalable manufacturing solutions.

With continuous technological advancements and rising demand for rapid and accurate testing solutions, the Diagnostic CDMO Market is expected to remain a critical component of the global healthcare ecosystem through 2033.

About Us

Business Market Insights is a market research platform that provides subscription services and consulting solutions across various industries including healthcare, technology, chemicals, electronics, and manufacturing. The company delivers in-depth market intelligence, competitive analysis, and strategic insights to help organizations make informed business decisions and identify emerging market opportunities.

Contact Us

Business Market Insights

Email: sales@businessmarketinsights.com